CN102526355A - Chinese medicinal compound preparation for resisting virus and treating flu and cold - Google Patents
Chinese medicinal compound preparation for resisting virus and treating flu and cold Download PDFInfo
- Publication number
- CN102526355A CN102526355A CN2012100417542A CN201210041754A CN102526355A CN 102526355 A CN102526355 A CN 102526355A CN 2012100417542 A CN2012100417542 A CN 2012100417542A CN 201210041754 A CN201210041754 A CN 201210041754A CN 102526355 A CN102526355 A CN 102526355A
- Authority
- CN
- China
- Prior art keywords
- chinese medicinal
- radix
- preparation
- flu
- antiviral therapy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 22
- 150000001875 compounds Chemical class 0.000 title claims abstract description 14
- 241000700605 Viruses Species 0.000 title abstract description 4
- 239000003814 drug Substances 0.000 claims abstract description 32
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims abstract description 15
- 239000002994 raw material Substances 0.000 claims abstract description 6
- 241000205585 Aquilegia canadensis Species 0.000 claims abstract description 5
- 239000002775 capsule Substances 0.000 claims abstract description 5
- 239000000203 mixture Substances 0.000 claims abstract description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 24
- 206010022000 influenza Diseases 0.000 claims description 22
- 241000628997 Flos Species 0.000 claims description 12
- 230000000840 anti-viral effect Effects 0.000 claims description 12
- 238000002560 therapeutic procedure Methods 0.000 claims description 12
- 239000000284 extract Substances 0.000 claims description 11
- 238000001035 drying Methods 0.000 claims description 10
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 10
- 238000002156 mixing Methods 0.000 claims description 9
- 239000000843 powder Substances 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 239000007788 liquid Substances 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 6
- 239000008187 granular material Substances 0.000 claims description 6
- 239000000463 material Substances 0.000 claims description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 5
- 239000000796 flavoring agent Substances 0.000 claims description 5
- 235000019634 flavors Nutrition 0.000 claims description 5
- 235000019359 magnesium stearate Nutrition 0.000 claims description 5
- 239000000741 silica gel Substances 0.000 claims description 5
- 229910002027 silica gel Inorganic materials 0.000 claims description 5
- 229920002472 Starch Polymers 0.000 claims description 4
- -1 correctives Substances 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 239000008107 starch Substances 0.000 claims description 4
- 235000019698 starch Nutrition 0.000 claims description 4
- 239000002671 adjuvant Substances 0.000 claims description 3
- 230000006837 decompression Effects 0.000 claims description 3
- 230000008021 deposition Effects 0.000 claims description 3
- 239000000706 filtrate Substances 0.000 claims description 3
- 239000012530 fluid Substances 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- 239000006228 supernatant Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
- 108010011485 Aspartame Proteins 0.000 claims description 2
- 229920001353 Dextrin Polymers 0.000 claims description 2
- 239000004375 Dextrin Substances 0.000 claims description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 2
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 claims description 2
- 229930006000 Sucrose Natural products 0.000 claims description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 2
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 claims description 2
- 239000000605 aspartame Substances 0.000 claims description 2
- 235000010357 aspartame Nutrition 0.000 claims description 2
- 229960003438 aspartame Drugs 0.000 claims description 2
- 239000011230 binding agent Substances 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 235000019425 dextrin Nutrition 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000008101 lactose Substances 0.000 claims description 2
- 239000000314 lubricant Substances 0.000 claims description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 2
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 2
- 229960001866 silicon dioxide Drugs 0.000 claims description 2
- 239000005720 sucrose Substances 0.000 claims description 2
- 239000006188 syrup Substances 0.000 claims description 2
- 235000020357 syrup Nutrition 0.000 claims description 2
- 239000000811 xylitol Substances 0.000 claims description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 2
- 235000010447 xylitol Nutrition 0.000 claims description 2
- 229960002675 xylitol Drugs 0.000 claims description 2
- 230000002155 anti-virotic effect Effects 0.000 claims 1
- 206010011224 Cough Diseases 0.000 abstract description 13
- 230000000694 effects Effects 0.000 abstract description 13
- 210000004072 lung Anatomy 0.000 abstract description 10
- 206010037660 Pyrexia Diseases 0.000 abstract description 6
- 238000012360 testing method Methods 0.000 abstract description 5
- 231100000331 toxic Toxicity 0.000 abstract description 4
- 230000002588 toxic effect Effects 0.000 abstract description 4
- 231100000419 toxicity Toxicity 0.000 abstract description 3
- 230000001988 toxicity Effects 0.000 abstract description 3
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 abstract description 2
- 238000011047 acute toxicity test Methods 0.000 abstract description 2
- 230000000857 drug effect Effects 0.000 abstract description 2
- 231100001252 long-term toxicity Toxicity 0.000 abstract description 2
- 230000003285 pharmacodynamic effect Effects 0.000 abstract description 2
- 235000015221 Bupleurum rotundifolium Nutrition 0.000 abstract 2
- 244000236521 Bupleurum rotundifolium Species 0.000 abstract 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 abstract 1
- 241000050051 Chelone glabra Species 0.000 abstract 1
- 241000576429 Forsythia suspensa Species 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 244000274050 Platycodon grandiflorum Species 0.000 abstract 1
- 235000006753 Platycodon grandiflorum Nutrition 0.000 abstract 1
- 238000006243 chemical reaction Methods 0.000 abstract 1
- 230000003111 delayed effect Effects 0.000 abstract 1
- 230000003467 diminishing effect Effects 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 229940041616 menthol Drugs 0.000 abstract 1
- 229940079593 drug Drugs 0.000 description 14
- 231100000614 poison Toxicity 0.000 description 8
- 244000052769 pathogen Species 0.000 description 7
- 239000003440 toxic substance Substances 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 241000725643 Respiratory syncytial virus Species 0.000 description 5
- 206010057190 Respiratory tract infections Diseases 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- 206010059866 Drug resistance Diseases 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 230000008961 swelling Effects 0.000 description 4
- 230000000954 anitussive effect Effects 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 230000036760 body temperature Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 238000005057 refrigeration Methods 0.000 description 3
- 231100000111 LD50 Toxicity 0.000 description 2
- 206010068319 Oropharyngeal pain Diseases 0.000 description 2
- 201000007100 Pharyngitis Diseases 0.000 description 2
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 2
- 206010061603 Respiratory syncytial virus infection Diseases 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 241000193998 Streptococcus pneumoniae Species 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 230000001741 anti-phlogistic effect Effects 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 2
- 231100001274 therapeutic index Toxicity 0.000 description 2
- 241000712461 unidentified influenza virus Species 0.000 description 2
- 208000031504 Asymptomatic Infections Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 206010014080 Ecchymosis Diseases 0.000 description 1
- 206010069767 H1N1 influenza Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 1
- 206010028748 Nasal obstruction Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 241000711504 Paramyxoviridae Species 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 241001113283 Respirovirus Species 0.000 description 1
- 208000036071 Rhinorrhea Diseases 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000009351 contact transmission Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 239000007919 dispersible tablet Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 231100000682 maximum tolerated dose Toxicity 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 229960003085 meticillin Drugs 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 150000007660 quinolones Chemical class 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 201000010740 swine influenza Diseases 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a Chinese medicinal compound preparation for resisting virus and treating flu and cold. The preparation consists of the following raw materials by weight: 300 to 600g of honeysuckle, 200 to 400g of indigowoad leaf, 200 to 400g of weeping forsythia capsule, 200 to 400g of Chinese thorowax root, 200 to 400g of baical skullcap root, 200 to 400g of platycodon grandiflorum, and 1 to 10g of menthol. Pharmacodynamic tests prove that honeysuckle and Chinese thorowax root anti-flu capsules have the effects of reducing fever, diminishing inflammation and relieving cough, wherein the effect of reducing fever is more remarkable. Acute toxicity tests prove that: the safe dosage of the Chinese medicinal composition is equivalent to 371.2 times that of maximum clinical dosage of a human. Long-term toxicity test researching results prove that: remarkable toxic changes or delayed toxicity reactions caused by medicament are not found. The Chinese medicinal compound preparation has the functions of clearing heat and removing toxicity, coursing wind and dissipating heat, and ventilating lung and relieving cough, and has the advantages of convenient use, controllable quality, definite drug effect and safety and reliability.
Description
Technical field
The present invention relates to a kind of antiviral therapy influenza, flu compound Chinese medicinal preparation, a kind of specifically treatment disease is seen fever with chills, headache, systemic pain, nasal obstruction, sneeze, rhinorrhea, pharyngalgia, cough, and red tongue with thin fur is white, the medicine of floating and rapid pulse etc.
Background technology
Respiratory tract infection (respiratory infection) is one of modal clinically, as human health to be had very big infringement disease; It can be asymptomatic inapparent infection; Also can jeopardize patient's life; Wherein quite a few has certain infectiousness, and it mainly contains bacterial infection and two kinds of approach of viral infection.Staphylococcus aureus, Pseudomonas aeruginosa and streptococcus pneumoniae are the encountered pathogenic bacterias that causes respiratory tract infection clinically; In recent years because a large amount of uses of antibacterials and constantly upgrading; Its drug resistance is in rising trend, and multi-drug resistant bacterias such as methicillin-resistant staphylococcus aureus (MRSA), quinolones resistant Pseudomonas Aeruginosa and the drug-fast streptococcus pneumoniae of penicillin occur, has brought many difficulties for clinical anti-infective therapy; In addition; Owing to clinical heavy dose is used antitumor drug in recent years, immunosuppressant causes patient's immunity degradation to cause various infection in the hospital, institute infects in the internal respiration road, mixed infection constantly increases, and the conditioned pathogen ratio rises; The extensive use of a large amount of broad ectrum antibiotic constantly strengthens bacterial drug resistance, and bacterial resistance has become a severe problem.Influenza virus (IFV) and respiratory syncytial virus (RSV) are two kinds of common viruses that cause respiratory system infection.H1N1 influenza virus in 2009 eruption and prevalence in worldwide has caused serious harm for human life and health entirely, makes prevention and treatment influenza become the vital task of antiviral research.RSV then is a kind of RNA viruses, belongs to Paramyxoviridae.This disease is through the air spittle and contact transmission closely.Since be used to treat at present IFV and RSV the medicine limitation, be prone to produce drug resistance, therefore seek new, effective preventing respiratory viruses medicine is imperative.At present; For respiratory tract infection, doctor trained in Western medicine mainly adopts antibiotic and antiviral drugs to carry out symptomatic treatment, but owing to above-mentioned or the like reason; The treatment drawback of chemicals manifests gradually; And traditional Chinese medicine has characteristics such as safety, good effect, many target spots, difficult generation drug resistance owing to adopt multiple compatibility of drugs prescription to form, and has certain advantage aspect the treatment respiratory tract infection.For removing the misery of extensive patients, we develop Chinese medicine, six types-Jin Chai of natural drug new drug KANGGAN JIAONANG, and prescription derives from experience well-known doctor's decades clinical experience side, by the seven flavor medicine prescription; Be legal medical material, do not contain the medicine of incompatibilitys such as toxicity medicine and eighteen incompatible medicaments, nineteen medicaments of mutual restraint, its reasonable recipe; Has heat-clearing and toxic substances removing, dispelling wind and heat pathogens, the effect of lung qi dispersing cough-relieving; Treating both the principal and secondary aspects of a disease, easy to use, quality controllable; Drug effect is definite, and safe and reliable advantage can satisfy the demand of extensive patients.
Summary of the invention
Technical problem to be solved by this invention provides the compound Chinese medicinal preparation of a kind of antiviral therapy influenza, flu, and this medicine has the effect of heat-clearing and toxic substances removing, dispelling wind and heat pathogens, lung qi dispersing cough-relieving.
Medicine of the present invention is processed by the following weight Chinese medicinal raw materials:
Flos Lonicerae 300～600g Folium Isatidis 200～400g Fructus Forsythiae 200～400g
Radix Bupleuri 200～400g Radix Scutellariae 200～400 Radix Platycodoniss 200～400g
Mentholum 1～10g
The preferred weight proportioning of each raw material of the present invention is:
Flos Lonicerae 400～500g Folium Isatidis 250～350g Fructus Forsythiae 250～350g
Radix Bupleuri 250～350g Radix Scutellariae 250～350 Radix Platycodoniss 250～350g
Mentholum 1～5g
The optimum weight proportioning of each raw material of the present invention is:
Flos Lonicerae 450g Folium Isatidis 300g Fructus Forsythiae 300g
Radix Bupleuri 300g Radix Scutellariae 300g Radix Platycodonis 300g
Mentholum 2g
Method for preparing of the present invention is: above seven flavors, and get Mentholum and be ground into fine powder, subsequent use; Get Radix Scutellariae and add 10 times of water gagings decoctions 3 times, 2 hours for the first time, second and third time each 1 hour, collecting decoction; Filter, relative density was 1.03～1.08 clear paste when filtrating was concentrated into 80 ℃, in 80 ℃ with 2mol/L hydrochloric acid solution adjust pH to 1.0～2.0, be incubated 1 hour; Left standstill 24 hours, and filtered, it is 5.0 that the deposition water is washed till pH value; It is 7.0 that reuse 70% ethanol is washed till pH value, and cold drying is subsequent use; Get Folium Isatidis, Fructus Forsythiae, Radix Platycodonis and add 8 times of water gagings and extract 3 times, each 2 hours, merge extractive liquid, filtered, and the clear paste of relative density 1.12～1.18 when filtrate decompression is concentrated into 60 ℃ adds ethanol and makes and contain the alcohol amount and reach 70%, and hold over night is got supernatant and filtered, and is subsequent use; Extracting honeysuckle, Radix Bupleuri add 8 times of amounts of 70% ethanol and extract 3 times, and each 1 hour, merge extractive liquid, filtered, and filtrating merges with above-mentioned pure alcohol deposit fluid; Concentrating under reduced pressure becomes thick paste, and the adding micropowder silica gel is an amount of, mixing, and drying under reduced pressure adds above-mentioned Radix Scutellariae extract; Be ground into fine powder, add appropriate amount of auxiliary materials, mixing is processed granule, drying; Add Mentholum fine powder and an amount of magnesium stearate, mixing is processed preparation, promptly gets.
Medicine of the present invention can add one or more pharmaceutic adjuvants as required; Pharmaceutic adjuvant can be diluent, binding agent, correctives, excipient, fluidizer, lubricant, disintegrating agent, like sucrose, dextrin, starch, lactose, xylitol, soluble starch, micropowder silica gel, microcrystalline Cellulose, aspartame, steviosin, magnesium stearate.
The present invention can process any clinical pharmaceutical preparation that is applicable to according to existing process of Chinese medicine preparation, comprises solid preparation (hard capsule, granule, tablet, dispersible tablet, soft capsule, drop pill, pill), liquid preparation (syrup, soft extract, oral liquid, mixture) etc.The preferred dosage form of the present invention is capsule, granule, tablet.
The present invention is by seven flavor Chinese prescriptions such as Flos Lonicerae, Folium Isatidis, and Flos Lonicerae is sweet, cold in the side, returns lung, the heart, stomach warp, has the effect of heat-clearing and toxic substances removing, dispelling wind and heat pathogens, is to be monarch drug; Folium Isatidis is bitter, cold, heat-clearing and toxic substances removing, blood cooling and ecchymoses removing, principal drug assistance Flos Lonicerae heat-clearing and toxic substances removing; Fructus Forsythiae is bitter, is slightly cold, and GUIXIN, lung, small intestine meridian have heat-clearing and toxic substances removing, dispersing swelling and dissipating binds, the merit of dispelling wind and heat pathogens, the normal and same usefulness of Flos Lonicerae, principal drug assistance loose lung meridian pathogenic heat, the gastric heat that clears away heart-fire poison; Radix Bupleuri is hot, bitter, be slightly cold and return liver, gallbladder, lung meridian, has and evacuates the merit of bringing down a fever, and the principal drug assistance Flos Lonicerae is evacuated and brings down a fever; Radix Scutellariae is bitter, cold, heat clearing and damp drying, and eliminating fire and detoxication is adjuvant drug, share with monarch-minister drug, has the power of eliminating fire and detoxication; Mentholum is hot, and cold has dispelling wind and heat pathogens, the clear sharp head, and sore-throat relieving, soothing the liver circulation of qi promoting is adjuvant drug altogether; Radix Platycodonis is bitter, hot, and is flat, returns lung meridian, lung qi dispersing, and sore-throat relieving eliminates the phlegm, and evacuation of pus is messenger drug.Full side plays the effect of heat-clearing and toxic substances removing, dispelling wind and heat pathogens, lung qi dispersing cough-relieving altogether.
The present invention through to the influence of heating rat temperature due to the yeast, to Oleum Tiglii cause the influence of mice auricle swelling, the results of pharmacodynamic test that ammonia is caused the influence of mouse cough shows: to the influence of heating rat temperature due to the yeast; The model control group rat is after modeling; Body temperature decreased in 1 hour; Constantly raise subsequently, the rising situation can judge that the rat fever model is successful.Positive controls, tried object height, in, the lift-off value of low dose group and negative fervescence value relatively; Difference does not have the significance meaning in 1～2 hour; Difference has significance meaning (P＜0.01) in 3～6 hours; Explain that the present invention can reduce the body temperature of heating rat due to the yeast, has the antipyretic effect; The auricle swelling degree that Oleum Tiglii causes the mice auricle swelling positive controls, tried the object height dose groups is lower than negative control group; Statistical analysis difference has significance meaning (P＜0.05); Show that high dose of the present invention and indometacin can suppress Oleum Tiglii and cause the mice ear effect, explain that the present invention has antiphlogistic effect; Among the present invention, low dose group all obviously prolongs mouse cough incubation period; With the negative control group comparing difference significance meaning (P＜0.01) is arranged; Positive controls also can prolong mouse cough incubation period, with the negative control group comparing difference significance meaning (P＜0.05) is arranged.Each organizes mouse cough time digit rate does not all have significant difference than negative control group.Show that the present invention can improve the cough that ammonia causes, has certain antitussive effect.
Experiment shows that the high, medium and low dosage of golden bavin KANGGAN JIAONANG all can be able to reduce the body temperature of heating rat due to the yeast, and refrigeration function is obvious; Gold bavin KANGGAN JIAONANG high dose can suppress Oleum Tiglii and cause the mice ear effect, explains that golden bavin KANGGAN JIAONANG has antiphlogistic effect, but with respect to refrigeration function a little less than; In the gold bavin KANGGAN JIAONANG, low dose group all obviously prolongs mouse cough incubation period but fails to reduce cough time digit rate, has certain antitussive effect.That aggregate analysis, golden bavin KANGGAN JIAONANG have is analgesic, the effect of antiinflammatory and antitussive, and wherein refrigeration function is more obvious.
Median lethal dose(LD 50) is not measured in acute toxicity test mouse stomach of the present invention administration; Its maximum tolerated dose is 37.12g/kg, and quite the clinical maximum consumption of people is 371.2 times.
Long term toxicity test result of study of the present invention shows that animal ingestion amount, hematological indices, blood parameters, blood electrolyte, each internal organs general appearance and histopathology etc. do not see that obvious drug-induced toxic changes and the retardance toxic reaction.
The outer result of the test of microbial body of the present invention shows that IFA and rsv infection are all had certain inhibitory action.Wherein golden bavin KANGGAN JIAONANG is respectively 3.24 ± 0.08 and 889.01 ± 22.63 μ gmL to inhibitory action therapeutic index and the medium effective concentration that IFV infects
-1Inhibitory action therapeutic index and medium effective concentration to rsv infection are 12.09 ± 0.35 and 42.40 ± 1.24 μ gmL
-1So this medicine is better to the effect of RSV, the present invention can be used for the infection that Respirovirus causes.
An important feature of the present invention is a pure Chinese medicinal preparation, and determined curative effect, toxic and side effects are little, can the antiviral therapy influenza, the compound preparation of flu, and help the patient to get well fast.Simultaneously, process capsule after, made things convenient for carrying and taking of patient, and quality controllable, safety good.
The specific embodiment
Realize further specifying through the following specific embodiment, but should not be understood that any restriction of the present invention to of the present invention.
Press the column weight amount and take by weighing raw material:
Flos Lonicerae 450g Folium Isatidis 300g Fructus Forsythiae 300g Radix Bupleuri 300g
Radix Scutellariae 300g Radix Platycodonis 300g Mentholum 2g
Method for preparing: above seven flavors, get Mentholum and be ground into fine powder, subsequent use; Get Radix Scutellariae and add 10 times of water gagings decoctions 3 times, 2 hours for the first time, second and third time each 1 hour, collecting decoction; Filter, relative density was 1.03～1.08 clear paste when filtrating was concentrated into 80 ℃, in 80 ℃ with 2mol/L hydrochloric acid solution adjust pH to 1.0～2.0, be incubated 1 hour; Left standstill 24 hours, and filtered, it is 5.0 that the deposition water is washed till pH value; It is 7.0 that reuse 70% ethanol is washed till pH value, and cold drying is subsequent use; Get Folium Isatidis, Fructus Forsythiae, Radix Platycodonis and add 8 times of water gagings and extract 3 times, each 2 hours, merge extractive liquid, filtered, and the clear paste of relative density 1.12～1.18 when filtrate decompression is concentrated into 60 ℃ adds ethanol and makes and contain the alcohol amount and reach 70%, and hold over night is got supernatant and filtered, and is subsequent use; Extracting honeysuckle, Radix Bupleuri add 8 times of amounts of 70% ethanol and extract 3 times, and each 1 hour, merge extractive liquid, filtered, and filtrating merges with above-mentioned pure alcohol deposit fluid; Concentrating under reduced pressure becomes thick paste, and the adding micropowder silica gel is an amount of, mixing, and drying under reduced pressure adds above-mentioned Radix Scutellariae extract; Be ground into fine powder, add appropriate amount of auxiliary materials, mixing is processed granule, drying; Add Mentholum fine powder and an amount of magnesium stearate, mixing incapsulates, and processes 1000, promptly gets.
Claims (7)
1. an antiviral therapy influenza, flu compound Chinese medicinal preparation is characterized in that it is to be processed by following Chinese medicine raw materials by weight proportion:
Flos Lonicerae 300～600g Folium Isatidis 200～400g Fructus Forsythiae 200～400g
Radix Bupleuri 200～400g Radix Scutellariae 200～400 Radix Platycodoniss 200～400g
Mentholum 1～10g.
2. a kind of antiviral therapy influenza according to claim 1, anti virus herb compound preparation is characterized in that this Chinese medicine processed by following materials of weight proportions component:
Flos Lonicerae 400～500g Folium Isatidis 250～350g Fructus Forsythiae 250～350g
Radix Bupleuri 250～350g Radix Scutellariae 250～350 Radix Platycodoniss 250～350g
Mentholum 1～5g.
3. a kind of antiviral therapy influenza according to claim 1, flu compound Chinese medicinal preparation is characterized in that this Chinese medicine processed by following materials of weight proportions component:
Flos Lonicerae 450g Folium Isatidis 300g Fructus Forsythiae 300g
Radix Bupleuri 300g Radix Scutellariae 300g Radix Platycodonis 300g
Mentholum 2g.
4. a kind of antiviral therapy influenza according to claim 1, flu compound Chinese medicinal preparation is characterized in that method for preparing is: above seven flavors, and get Mentholum and be ground into fine powder, subsequent use; Get Radix Scutellariae and add 10 times of water gagings decoctions 3 times, 2 hours for the first time, second and third time each 1 hour, collecting decoction; Filter, relative density was 1.03～1.08 clear paste when filtrating was concentrated into 80 ℃, in 80 ℃ with 2mol/L hydrochloric acid solution adjust pH to 1.0～2.0, be incubated 1 hour; Left standstill 24 hours, and filtered, it is 5.0 that the deposition water is washed till pH value; It is 7.0 that reuse 70% ethanol is washed till the pH value, and cold drying is subsequent use; Get Folium Isatidis, Fructus Forsythiae, Radix Platycodonis and add 8 times of water gagings and extract 3 times, each 2 hours, merge extractive liquid, filtered, and the clear paste of relative density 1.12～1.18 when filtrate decompression is concentrated into 60 ℃ adds ethanol and makes and contain the alcohol amount and reach 70%, and hold over night is got supernatant and filtered, and is subsequent use; Extracting honeysuckle, Radix Bupleuri add 8 times of amounts of 70% ethanol and extract 3 times, and each 1 hour, merge extractive liquid, filtered, and filtrating merges with above-mentioned pure alcohol deposit fluid; Concentrating under reduced pressure becomes thick paste, and the adding micropowder silica gel is an amount of, mixing, and drying under reduced pressure adds above-mentioned Radix Scutellariae extract; Be ground into fine powder, add appropriate amount of auxiliary materials, mixing is processed granule, drying; Add Mentholum fine powder and an amount of magnesium stearate, mixing is processed preparation, promptly gets.
5. a kind of antiviral therapy influenza according to claim 4, flu compound Chinese medicinal preparation, wherein appropriate amount of auxiliary materials is diluent, binding agent, correctives, excipient, fluidizer, lubricant, disintegrating agent.
6. a kind of antiviral therapy influenza according to claim 4, flu compound Chinese medicinal preparation, wherein adjuvant is one or more in sucrose, dextrin, starch, lactose, xylitol, soluble starch, micropowder silica gel, microcrystalline Cellulose, aspartame, steviosin, the magnesium stearate.
7. a kind of antiviral therapy influenza according to claim 4, flu compound Chinese medicinal preparation, wherein preparation is a kind of in capsule, granule, tablet, soft extract, mixture, syrup, the pill.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012100417542A CN102526355A (en) | 2012-02-23 | 2012-02-23 | Chinese medicinal compound preparation for resisting virus and treating flu and cold |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012100417542A CN102526355A (en) | 2012-02-23 | 2012-02-23 | Chinese medicinal compound preparation for resisting virus and treating flu and cold |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102526355A true CN102526355A (en) | 2012-07-04 |
Family
ID=46335175
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2012100417542A Pending CN102526355A (en) | 2012-02-23 | 2012-02-23 | Chinese medicinal compound preparation for resisting virus and treating flu and cold |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102526355A (en) |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102784243A (en) * | 2012-08-01 | 2012-11-21 | 青岛绿曼生物工程有限公司 | Pure Chinese medicine composition for treating cattle flu and preparation method of same |
| CN103656567A (en) * | 2013-11-21 | 2014-03-26 | 杨莉 | Traditional Chinese medicine composition for treating influenza |
| CN104111295A (en) * | 2014-07-24 | 2014-10-22 | 神威药业集团有限公司 | Method for controlling quality of Chinese herbal preparation |
| CN104352601A (en) * | 2014-10-11 | 2015-02-18 | 中山百鸥医药科技有限公司 | Traditional Chinese medicine composition for treating influenza and preparation method thereof |
| CN104623082A (en) * | 2015-01-30 | 2015-05-20 | 吉林修正药业新药开发有限公司 | Traditional Chinese medicine for treating wind-heat cold and preparation method of traditional Chinese medicine |
| CN106619857A (en) * | 2016-12-05 | 2017-05-10 | 张明 | Traditional Chinese medicine composition for treating cattle chlamydia diseases |
| CN107632075A (en) * | 2017-08-08 | 2018-01-26 | 武汉双龙药业有限公司 | Golden three kinds of component contents of bavin KANGGAN JIAONANG while assay method and its HPLC fingerprint map construction methods |
| CN108743836A (en) * | 2018-08-27 | 2018-11-06 | 维康腾达生物科技有限公司 | A kind of anti virus herb composition and preparation method thereof |
| CN113521210A (en) * | 2020-04-17 | 2021-10-22 | 天士力医药集团股份有限公司 | Chinese medicinal composition containing herba Moslae |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1634261A (en) * | 2004-11-02 | 2005-07-06 | 贵阳新天药业股份有限公司 | Capsule for treating cold and cough and its preparation and detection method |
| CN101690745A (en) * | 2009-10-30 | 2010-04-07 | 福州市仓山区金点子信息咨询有限公司 | Chinese medicinal composition for preventing and treating flu |
-
2012
- 2012-02-23 CN CN2012100417542A patent/CN102526355A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1634261A (en) * | 2004-11-02 | 2005-07-06 | 贵阳新天药业股份有限公司 | Capsule for treating cold and cough and its preparation and detection method |
| CN101690745A (en) * | 2009-10-30 | 2010-04-07 | 福州市仓山区金点子信息咨询有限公司 | Chinese medicinal composition for preventing and treating flu |
Non-Patent Citations (4)
| Title |
|---|
| SHUANG-CHENG MA ET AL.: "Antiviral Chinese medicinal herbs against respiratory syncytial virus", 《JOURNAL OF ETHNOPHARMACOLOGY》 * |
| 国家药典委员会: "《中华人民共和国药典2010年版一部》", 31 January 2010, 化学工业出版社 * |
| 翟保同等: "黄芩苷提取工艺研究", 《中国医药导报》 * |
| 赵士冶等: "高效液相色谱法测定感冒止咳颗粒中黄芩苷含量", 《中国现代药物应用》 * |
Cited By (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102784243A (en) * | 2012-08-01 | 2012-11-21 | 青岛绿曼生物工程有限公司 | Pure Chinese medicine composition for treating cattle flu and preparation method of same |
| CN102784243B (en) * | 2012-08-01 | 2014-07-09 | 青岛绿曼生物工程有限公司 | Pure Chinese medicine composition for treating cattle flu and preparation method of same |
| CN103656567A (en) * | 2013-11-21 | 2014-03-26 | 杨莉 | Traditional Chinese medicine composition for treating influenza |
| CN104111295A (en) * | 2014-07-24 | 2014-10-22 | 神威药业集团有限公司 | Method for controlling quality of Chinese herbal preparation |
| CN104352601A (en) * | 2014-10-11 | 2015-02-18 | 中山百鸥医药科技有限公司 | Traditional Chinese medicine composition for treating influenza and preparation method thereof |
| CN104623082A (en) * | 2015-01-30 | 2015-05-20 | 吉林修正药业新药开发有限公司 | Traditional Chinese medicine for treating wind-heat cold and preparation method of traditional Chinese medicine |
| CN104623082B (en) * | 2015-01-30 | 2018-01-12 | 吉林修正药业新药开发有限公司 | A kind of Chinese medicine and preparation method for treating wind-heat cold |
| CN106619857A (en) * | 2016-12-05 | 2017-05-10 | 张明 | Traditional Chinese medicine composition for treating cattle chlamydia diseases |
| CN107632075A (en) * | 2017-08-08 | 2018-01-26 | 武汉双龙药业有限公司 | Golden three kinds of component contents of bavin KANGGAN JIAONANG while assay method and its HPLC fingerprint map construction methods |
| CN108743836A (en) * | 2018-08-27 | 2018-11-06 | 维康腾达生物科技有限公司 | A kind of anti virus herb composition and preparation method thereof |
| CN113521210A (en) * | 2020-04-17 | 2021-10-22 | 天士力医药集团股份有限公司 | Chinese medicinal composition containing herba Moslae |
| CN113521210B (en) * | 2020-04-17 | 2024-04-16 | 天士力医药集团股份有限公司 | Chinese medicinal composition containing herba Moslae |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102526355A (en) | Chinese medicinal compound preparation for resisting virus and treating flu and cold | |
| CN101601830B (en) | Chinese medicinal preparation for treating cold and preparation method thereof | |
| CN102784282A (en) | Medicine for clearing heat, removing toxicity and reducing fever | |
| CN104547496B (en) | A kind of Chinese medicine composition to moisten the lung and relieve the cough and preparation method thereof | |
| CN103977314A (en) | Medicinal composition for treating respiratory diseases as well as preparation method and application of medicinal composition | |
| CN105412749A (en) | Medicine for treating infantile pneumonia with dyspnea and cough and preparation method and application method thereof | |
| CN101978983B (en) | Chinese medicinal composition for treating acute upper respiratory infection and preparation method thereof | |
| CN104013846A (en) | Traditional Chinese medicine composition for treating dental ulcer and application thereof | |
| CN102210773B (en) | Chinese medicinal cataplasm for treating infantile pneumonia, preparation method thereof and application thereof | |
| CN101134092A (en) | Traditional Chinese medicine compound preparations for treating respiratory disease and method for preparing the same | |
| CN103432265A (en) | Traditional Chinese medicinal composition preparation for treating fever in children and preparation method thereof | |
| CN102552509A (en) | Traditional Chinese medicine combination for reducing heat and relieving cough | |
| CN102357176B (en) | Anti-cold traditional Chinese medicine composition | |
| CN101837046A (en) | Anti-virus Chinese medicinal preparation and preparation method thereof | |
| CN103006780B (en) | Traditional Chinese medicinal composition for treating allergic rhinitis and method for preparing same | |
| CN102429980A (en) | Cold granules and preparation method thereof | |
| CN102429979A (en) | A Chinese medicinal composition for treating common cold, and its preparation method | |
| CN103566029B (en) | Pharmaceutical composition for treating respiratory diseases and preparation method and usage thereof | |
| CN103405503A (en) | Traditional Chinese medicine compound preparation for treating acute mastitis and preparation method thereof | |
| CN103040939A (en) | Traditional Chinese medicine composition for treating cold, as well as preparation method and application thereof | |
| CN102429982A (en) | Traditional Chinese medicine granules for treating cold and preparation method thereof | |
| CN101934048B (en) | Traditional Chinese medicine compound preparation for treating respiratory disease and preparation method thereof | |
| CN106491692A (en) | A kind of coldrex | |
| CN104435133A (en) | Medicament for reducing fever | |
| CN102600287B (en) | Compound medicine for treating toothache |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB03 | Change of inventor or designer information |
Inventor after: Cai Zeyu Inventor after: Li Chongming Inventor after: Feng Bin Inventor before: Xu Nenggao Inventor before: Yu Yuehui Inventor before: Yuan Feng |
|
| COR | Change of bibliographic data | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20120704 |
|
| RJ01 | Rejection of invention patent application after publication |